We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+50.74%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.11B
AUM Growth
+$318M
Cap. Flow
+$101M
Cap. Flow %
9.09%
Top 10 Hldgs %
61.72%
Holding
56
New
18
Increased
10
Reduced
10
Closed
12

Top Buys

1
ANAB icon
AnaptysBio
ANAB
+$46.5M
2
ARVN icon
Arvinas
ARVN
+$39.2M
3
ASMB icon
Assembly Biosciences
ASMB
+$35.2M
4
IPHA
Innate Pharma
IPHA
+$27.9M
5
MRUS
Merus
MRUS
+$25M

Top Sells

1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$69.3M
2
ARGX icon
argenx
ARGX
+$44.5M
3
SLDB icon
Solid Biosciences
SLDB
+$34.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$14.3M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$8.42M

Sector Composition

1 Healthcare 87.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PVLA
26
Palvella Therapeutics
PVLA
$2.26B
$9.18M 0.83%
+31,690
New +$8.79M
FATE icon
27
Fate Therapeutics
FATE
$324M
$8.83M 0.8%
+451,354
New +$7.17M
MRTX
28
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.38M 0.76%
65,000
+20,779
+47% +$2M
RCUS icon
29
Arcus Biosciences
RCUS
$3.44B
$7.37M 0.66%
729,905
-24,600
-3% -$207K
EOLS icon
30
Evolus
EOLS
$377M
$7.3M 0.66%
+600,000
New +$8.46M
EIGR
31
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$6.7M 0.6%
14,978
-20,357
-58% -$7.22M
SVRA icon
32
Savara
SVRA
$1.13B
$6.42M 0.58%
+1,432,664
New +$1.72M
IOVA icon
33
Iovance Biotherapeutics
IOVA
$2.23B
$5.91M 0.53%
+213,647
New +$4.86M
RUBY
34
DELISTED
Rubius Therapeutics, Inc
RUBY
$5M 0.45%
525,877
+265,725
+102% +$2.57M
CYCN icon
35
Cyclerion Therapeutics
CYCN
$15.8M
$4.93M 0.44%
90,550
+51,740
+133% +$4.83M
XFOR icon
36
X4 Pharmaceuticals
XFOR
$360M
$4.45M 0.4%
+13,847
New +$4.97M
CRVS icon
37
Corvus Pharmaceuticals
CRVS
$1.25B
$4.01M 0.36%
+737,612
New +$2.58M
ACRS icon
38
Aclaris Therapeutics
ACRS
$793M
$3.94M 0.36%
+2,087,312
New +$3.46M
IGMS
39
DELISTED
IGM Biosciences
IGMS
$3.82M 0.34%
100,000
– –
TCRR
40
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.42M 0.31%
+239,500
New +$3.7M
CTMX icon
41
CytomX Therapeutics
CTMX
$788M
$3.41M 0.31%
+410,000
New +$2.77M
SURF
42
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$2.45M 0.22%
1,301,713
-247,175
-16% -$412K
VCEL icon
43
Vericel Corp
VCEL
$2.38B
$2.28M 0.21%
131,001
– –
UROV
44
DELISTED
Urovant Sciences Ltd.
UROV
$411K 0.04%
+26,468
New +$287K
ASMB icon
45
CALL
Assembly Biosciences
ASMB
$531M
– –
-41,525
Closed -$4.9M
AUTL
46
Autolus Therapeutics
AUTL
$383M
– –
-69,155
Closed -$859K
CRIS icon
47
Curis
CRIS
$9.02M
– –
-7,456
Closed -$6.68M
GOSS icon
48
CALL
Gossamer Bio
GOSS
$83.2M
– –
-800,000
Closed -$13.4M
LRMR icon
49
Larimar Therapeutics
LRMR
$384M
– –
-162,042
Closed -$1.44M
NXTC icon
50
NextCure
NXTC
$24.4M
– –
-20,875
Closed -$7.73M
1
2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $2.36B AUM 68.36% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's Q4 2019 Portfolio in Review

As of Q4 2019, EcoR1 Capital held 56 positions worth $1.11B, up 40% from $792M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

EcoR1 Capital deployed $101M of net new capital in Q4 2019, opening 18 new positions and adding to 10 existing holdings. Its largest new stake was AnaptysBio: 1,966,100 shares worth $31.9M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 79% a quarter earlier.

On the sell side, the largest reduction was argenx, an estimated $44.5M trimmed.

  • EcoR1 Capital's largest Q4 2019 buy was AnaptysBio: 1,966,100 shares worth $31.9M.
  • EcoR1 Capital added most to Assembly Biosciences in Q4 2019, an estimated $35.2M increase.
  • EcoR1 Capital's biggest Q4 2019 reduction was argenx, cutting an estimated $44.5M.
  • EcoR1 Capital fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $69.3M.
  • EcoR1 Capital's ten largest holdings make up 62% of its $1.11B portfolio in Q4 2019.
  • EcoR1 Capital opened 18 new positions and closed 12 in Q4 2019.
  • EcoR1 Capital's portfolio value rose 40% quarter-over-quarter to $1.11B.

Based on EcoR1 Capital's 13F filing for Q4 2019, filed 14 Feb 2020.